MPM BioImpact’s Sarepta Therapeutics SRPT Stock Holding History

MPM BioImpact’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-70,000	Closed	-$1.51M	–	47
2025 Q4	$1.51M	Sell	70,000 -630,000	-90%	-$13.3M	0.17%	37
2025 Q3	$13.5M	Buy	700,000 +378,304	+118%	+$6.74M	2.21%	21
2025 Q2	$5.5M	Buy	+321,696	New	+$13.7M	0.95%	37

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MPM BioImpact's SRPT Position: Q1 2026 in Review

MPM BioImpact sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 70,000 shares — an estimated $1.51M sold.

MPM BioImpact first reported a position in SRPT in Q2 2025 and held it in 3 quarters. The position peaked at $13.5M in Q3 2025. 344 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

MPM BioImpact reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
MPM BioImpact sold 70,000 Sarepta Therapeutics shares in Q1 2026, an estimated $1.51M.
MPM BioImpact first reported a position in Sarepta Therapeutics in Q2 2025 and held it in 3 quarters.
MPM BioImpact's Sarepta Therapeutics position peaked at $13.5M in Q3 2025.
344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on MPM BioImpact's 13F filing for Q1 2026, filed 15 May 2026.